Overview

A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis

Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
This study will evaluate whether an early positive response to once-monthly oral ibandronate in treatment-naive participants with postmenopausal osteoporosis is predictive of efficacy later in treatment. The anticipated time on study treatment is 6 months, and the target sample size is 360 individuals.
Phase:
Phase 4
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Diphosphonates
Ibandronic Acid